SUN PHARMACEUTICAL INDUSTRIES LTD.

Sun Pharmaceutical Industries Ltd has received no-objection letters from both the National Stock Exchange of India (NSE) and BSE Limited (BSE) for the reclassification of certain individuals from the 'Promoter Group' to the 'Public' category. This reclassification is in accordance with Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company had previously intimated about this process on May 14, 22, and 26, 2026. The individuals whose status is being reclassified include Krishna Vrundavandas Valia, Sudhir Vrundavandas Valia, and Raksha Sudhir Valia. Sun Pharma is required to ensure compliance with subsequent disclosure requirements related to this reclassification.

Sun Pharmaceutical Industries Limited announced that all resolutions presented at its 34th Annual General Meeting (AGM), held on July 31, 2026, were passed by the shareholders with the requisite majority. The company confirmed that the voting results and the Scrutinizer's Report are available on its website. The resolutions will become effective as per applicable laws. The AGM notice was dated July 06, 2026.

Sun Pharmaceutical Industries Limited announced the conclusion of its Board of Directors meeting held on July 31, 2026. The meeting commenced at 10:50 A.M., was adjourned for a break, and resumed, concluding at 3:40 P.M. The company provided this update further to its earlier communication on the same date. No specific outcomes or decisions from the meeting were detailed in this announcement.

Sun Pharma opened FY27 with consolidated revenue of ₹15,300 Cr, up 10.5% YoY (+4.7% QoQ), a healthy topline print led by India formulations (+16% to ₹5,475 Cr, taking Pharmarack market share to 8.5% from 8.2%) and Global Innovative Medicines (+12.8% to US$351 mn, 21.9% of sales). Reported consolidated PAT of ₹2,895 Cr looks striking at +26% YoY, but that jump is almost entirely a base effect: the year-ago quarter absorbed a ~₹717 Cr net exceptional loss (Taro's US$62 mn EPP legal settlement plus the SCD-044 write-off), while this quarter carries a smaller ₹195 Cr net exceptional (₹167 Cr Organon deal costs and a labour-code charge). Stripping both sides out, adjusted PAT of ₹3,089 Cr grew just 3.1% — the number the print should be judged on. The real operational signal is margin, not headline profit. EBITDA rose only 2.7% to ₹4,418 Cr and EBITDA margin compressed 220 bps to 28.9% from 31.1% a year ago, even as gross margin ticked up to 80.5%. The squeeze sits below the gross line — employee costs (+15% YoY) under the New Labour Codes and elevated launch-related spend for LEQSELVI/UNLOXCYT, which management had flagged as factored into the FY27 plan. R&D was ₹826 Cr at 5.4% of sales, running below the 6–7% the company guided, softening the reported margin further. Geography drove the mix: US formulations fell 9.7% YoY to US$427 mn as generics (including lenalidomide) eroded, only partly cushioned by innovative medicines; Emerging Markets grew 4.2% and RoW was flat. This is why consolidated revenue (+10.5%) far outpaced standalone (+2.6% to ₹5,741 Cr) — the India entity is steady but subsidiary/specialty momentum carries the group. Against the ~11% revenue and 7–11% PAT-decline that street previews modelled, the topline landed roughly in line and margins beat the 26–27.5% preview band, while underlying profit growth (~3%) undershot the double-digit hopes some carried in. The quarter also advanced the strategic agenda: Organon shareholders approved the US$11.75 bn acquisition on July 24, and management reiterated a close by Q4FY27/early 2027 — with more transaction costs to come. Semaglutide approvals in Brazil and South Africa and a maintained US$3.4 bn net-cash position round out a quarter where the strategy progressed but the P&L, on a like-for-like basis, was steady rather than strong.

Sun Pharmaceutical Industries Limited has received approval from Brazil's ANVISA to manufacture and market semaglutide injection. This drug is used for type 2 diabetes management. Sun Pharma plans to launch the product in Brazil within days, in partnership with Hypera Pharma. The product will be available as a pre-filled, multi-dose injectable pen in two strengths, offering a once-weekly dosing regimen. The Brazilian semaglutide injectable market is valued at approximately USD 413 million.

Sun Pharmaceutical Industries Ltd announced that its partner, Philogen, has resubmitted the Marketing Authorization Application (MAA) for Nidlegy™ to the European Medicines Agency (EMA). Nidlegy™ is an investigational product for the neoadjuvant treatment of locally advanced, fully resectable melanoma. The updated submission includes data from a Phase III PIVOTAL study with longer patient follow-up (33 months vs. 21 months) and additional post-hoc analyses. Clinical data supporting the resubmission have been accepted for publication in the Journal of Clinical Oncology. Philogen is also addressing outstanding clinical and Chemistry, Manufacturing, and Controls (CMC) questions from the previous review. Sun Pharma has partnered with Philogen for the treatment of Skin Cancers in Europe, New Zealand, and Australia.

Sun Pharmaceutical Industries Limited announced that Organon & Co. stockholders have approved the merger transaction, a significant step towards Organon becoming a wholly owned subsidiary of Sun Pharma Holdings USA, Inc. This approval is a key milestone, though the acquisition is still contingent on satisfying remaining customary closing conditions, including regulatory approvals. Sun Pharma, a leading global pharmaceutical company, is a major player in India and holds strong positions in the US and emerging markets with a diverse portfolio including innovative medicines.

Sun Pharmaceutical Industries Limited has received approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market a generic version of semaglutide injection. This approval allows Sun Pharma to offer a treatment for adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise. The product will be available in two strengths and is planned for launch in the coming days. This marks South Africa as the second market, after India, where Sun Pharma has secured approval for generic semaglutide, highlighting the company's capability in developing complex generics for diverse markets and its commitment to improving access to essential medicines.

Sun Pharmaceutical Industries Ltd has announced that its Board of Directors will convene on July 31, 2026. The primary agenda for this meeting is to consider and approve the Unaudited Standalone and Consolidated Financial Results for the first quarter ended June 30, 2026. The company also confirmed that the trading window, which was closed from July 1, 2026, will remain shut until August 2, 2026, in accordance with SEBI regulations.

Sun Pharmaceutical Industries Ltd has announced its 34th Annual General Meeting (AGM) to be held on Friday, July 31, 2026, at 04:00 P.M. IST through videoconferencing. The company has also released its Annual Report for the Financial Year 2025-26. Key dates for shareholders include a cut-off date of July 24, 2026, for voting eligibility, with remote e-voting commencing on July 27, 2026, and concluding on July 30, 2026. The Annual Report highlights the company's strategy focused on innovative therapies and its diversified business model, with the Innovative Medicines business contributing 22% of consolidated sales in FY26.